Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 13 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
In addition to revenue exceeding the forecast because promotional activities for scopes equipped with EDOF technology and the endoscopic ultrasound observation system “EU-ME3” in the North American market proved effective, gains on the sale of buildings owned overseas were recognized as other income, among other factors.
| Item | Details |
|---|---|
| Net Sales | ¥998,000 million → ¥1,010,676 million（＋1.3％） |
| Operating profit | 87,000～75,000 → ¥97,120 million（＋11.6～＋29.5％） |
| Profit attributable to owners of the parent | 59,000～50,000 → ¥68,172 million（＋15.5～＋36.3％） |
| Net income per share | 53.07～44.97 → 61.32 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 February 2026 |
| Previous-period results | Revenue ¥997,332 million, operating profit ¥162,462 million, adjusted operating profit ¥188,509 million, profit before tax ¥159,070 million, profit attributable to owners of the parent ¥117,855 million, basic earnings per share ¥102.99 |
| Reason for the revision | In addition to revenue exceeding the forecast because promotional activities for scopes equipped with EDOF technology and the endoscopic ultrasound observation system “EU-ME3” in the North American market proved effective, gains on the sale of buildings owned overseas were recognized as other income, among other factors. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the gastrointestinal endoscopy solutions business, promotional activities for scopes equipped with EDOF technology and the “EU-ME3” in the North American market proved effective, resulting in revenue exceeding the forecast. In addition, profit items exceeded the forecast due in part to the recognition of gains on the sale of buildings owned overseas as other income.